Scully M F, Toh C H, Hoogendoorn H, Manuel R P, Nesheim M E, Solymoss S, Giles A R
Department of Haematology, Royal Victoria Hospital Montreal, Quebec, Canada.
Thromb Haemost. 1993 May 3;69(5):448-53.
Activation and inactivation of protein C during the clinical course of disseminated intravascular coagulation (DIC) was studied in three patients by qualitative (Western blotting) and quantitative (ELISA) analysis and the intensity of procoagulant activity monitored by the measurement of thrombin and factor Xa antithrombin III complexes. In one patient, inhibitor complexes of APC with protein C inhibitor (PCI) and alpha 1-antitrypsin (alpha 1-AT) were observed and the latter predominated at presentation. Both disappeared during the development of remission but the loss of alpha 1-AT complexes preceded PCI complexes which on Western blotting appeared to increase in intensity prior to disappearance. The two other patients bled to death from uncontrollable haemorrhage. In both cases, APC/inhibitor complexes with alpha 2-macroglobulin (alpha 2-M) in addition to PCI and alpha 1-AT were detected and persisted until death. Although PCI appeared to be the primary inhibitor in all three cases, alpha 1-antitrypsin and particularly alpha 2-macroglobulin appeared to assume greater roles in the two fatal cases. These data are similar to previous findings in an experimental animal model of DIC that suggested that alpha 2-macroglobulin and alpha 1-antitrypsin become more important inhibitors of APC as the primary inhibitor PCI is consumed in the face of a sustained procoagulant challenge.
通过定性(蛋白质印迹法)和定量(酶联免疫吸附测定法)分析,以及通过测量凝血酶和因子Xa抗凝血酶III复合物来监测促凝活性的强度,对3例弥散性血管内凝血(DIC)临床病程中蛋白C的激活和失活情况进行了研究。在1例患者中,观察到活化蛋白C(APC)与蛋白C抑制剂(PCI)和α1-抗胰蛋白酶(α1-AT)的抑制复合物,且在疾病初发时后者占主导。在病情缓解过程中,两者均消失,但α1-AT复合物的消失先于PCI复合物,在蛋白质印迹法中,PCI复合物在消失前强度似乎增加。另外2例患者死于无法控制的出血。在这2例中,除了PCI和α1-AT外,还检测到APC与α2-巨球蛋白(α2-M)的抑制复合物,且持续到死亡。尽管在所有3例中PCI似乎都是主要抑制剂,但在2例致命病例中,α1-抗胰蛋白酶,尤其是α2-巨球蛋白似乎发挥了更大作用。这些数据与先前在DIC实验动物模型中的发现相似,即面对持续的促凝挑战,随着主要抑制剂PCI被消耗,α2-巨球蛋白和α1-抗胰蛋白酶成为APC更重要的抑制剂。